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Abstract: Monocyclic b-lactams revive the research field
on antibiotics, which are threatened by the emergence of
resistant bacteria. A six-step synthetic route was devel-
oped, providing easy access to new 3-amino-1-carboxy-
methyl-4-phenyl-b-lactams, of which the penicillin-binding
protein (PBP) inhibitory potency was demonstrated bio-
chemically.
In light of the rapidly escalating bacterial resistance problem,
antibiotic discovery remains a highly important drug discovery
endeavour.[1] To break away from traditional bicyclic b-lactam
scaffolds, the research on monocyclic b-lactam antibiotics
gains in importance, as we previously demonstrated through a
three-decade literature overview.[2] Taking into account the as-
sembled state-of-the-art, and combining the structural proper-
ties of aztreonam (the only FDA-approved monobactam), the
nocardicins (the first described, natural monocyclic b-lactams)
and late-generation cephalosporins, our group recently studied
a new pharmacophore 1 to mimic d-alanyl-d-alanine, the natu-
ral substrate of the penicillin-binding proteins, playing a crucial
role in the bacterial cell wall biosynthesis (Figure 1). Using a
virtual screening approach as an onset, a ten-step synthetic
pathway was developed towards a model library of 4-unsubsti-
tuted b-lactams 1, characterised by diverse side chains ’R’. a-
Benzylidene-substituted analogue 1A was promoted to
become our first hit, favoured with promising PBP inhibitory
activity and high b-lactamase stability. In order to gain addi-
tional insights in the chemistry and structure–activity relation-
ships of these complex b-lactams, an explorative study on syn-
thetic routes towards C4-substituted analogues 2 was now ini-
tiated, holding on to the same design objectives (Figure 1). In
light of synthetic feasibility, 4-phenyl-b-lactams 2 were target-
ed first to provide a proof of concept. Their synthesis was per-
ceived to be achievable through functionalisation, in a similar
way as previously described,[3] of 3-amino-1-carboxymethyl-b-
lactams. As opposed to C4-unsubstituted b-lactams, C4-substi-
tuted variants can be easily prepared via Staudinger’s ketene-
imine [2+2]-cyclocondensation.[4] To date, this is one of the
most renowned and versatile methods for the construction of
the four-membered amide ring system and is often selected
for its simplicity in reaction procedures and predictability of
the stereochemical outcome.[5] For the synthesis of 3-amino-b-
lactams specifically, phthalimido- (FtN) and azido-containing
ketenes are typically employed.[6] As a means to shorten the
synthetic pathway as much as possible, the variable side chain
’R’ could be introduced directly in the amine part of the imine.
Indeed, when protected a-amino acids would be used as
cheap and easily available substrates and condensed with ben-
zaldehyde, the a-functionalised carboxymethyl moiety could
be installed quite easily onto the resulting b-lactam N1-posi-
tion. Based on the in silico design criteria regarding the a-side
chain ’R’ (Figure 1c),[3] several divergent a-amino acids were se-
lected to i. optimise the synthetic procedures (l-/dl-Phe); ii. in-
troduce terminal hydrogen bond donors or acceptors (l-Glu, l-
Trp and l-/d-Met, for oxidation to sulphones); and iii. change
the linker type to aromatic nocardicin-like motifs (d-Phg).[2]
Taking all the above into account, l-phenylalanine 3A (R=
Bn) as a model substrate was converted to the corresponding
methyl ester 4A by means of 2,2-dimethoxypropane and hy-
drochloric acid (Method A, Scheme 1, Table 1). The resulting
amine HCl salt was converted to the free base and subse-
quently condensed with benzaldehyde, affording aldimine 5A
in quantitative yield (Method C). Also the racemic starting ma-
terial 3A’ (dl-Phe) was converted in this way in view of HPLC
analysis using a chiral stationary phase (’chiral HPLC’) at a later
stage. Meanwhile, N-phthaloylglycine 6 was converted to the
corresponding glycyl chloride 7. After dehydrochlorination of
acid chloride 7 using triethylamine, the in situ generated
ketene was coupled with imines 5A-A’ to yield 4-phenyl-3-
phthalimidoazetidin-2-ones 8A-A’. Profound variation of the
Staudinger reaction conditions was necessary to enhance the
conversion rate and yield. The optimised set of reaction param-
eters and corresponding reaction outcomes are displayed in
Table 1. As expected, comparison of the results of Methods E
and F, showed that a higher amount of trans-isomer was ob-
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tained when 2,6-lutidine was used as a base in boiling tolu-
ene.[5] The accessibility of both cis- and trans-isomers was con-
sidered an asset with respect to future evaluation of the bio-
logical potency of the corresponding target products 2.
Next, phthaloyl deprotection of compounds 8A-A’ using hy-
drazine hydrate furnished 3-aminoazetidin-2-ones 9A-A’
(Table 2, Scheme 2).[7] In the next step, the obtained free
amines were coupled with 2-(2-aminothiazol-4-yl)-2-(methoxy-
imino)acetic acid (2-ATMO, predominantly syn) in alkaline envi-
ronment using O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluroni-
um tetrafluoroborate (TBTU) as a coupling reagent. The result-
ing cyclic amides 10A-A’ were obtained in variable yields of
Figure 1. Design strategy. [a] 3-Amino-1-carboxymethyl-b-lactam, mimicking the natural PBP substrate, d-alanyl-d-alanine, and enabling crucial molecular in-
teractions with the enzyme’s active site; [b] Optimised 2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido substituent;[2] [c] Variable side chain embedding a
lipophilic linker and terminal hydrogen bond-donating or -accepting functionalities, enabling additional non-covalent interactions with the key active site resi-
dues.
Scheme 1. Staudinger synthesis of Ft-protected 3-amino-1-methoxycarbonylmethyl-4-phenyl-b-lactams 8.
Table 1. Optimised synthesis of a-substituted 3-amino-1-methoxycarbonylmethyl-4-phenylazetidin-2-ones 8.
Compound
(Amino acid)
Esterification Imination Staudinger synthesis
Method 4 [%] (ee)[a] Method 5 [%] (ee)[a] Method
(Eq. base; Eq. 7)
dr before purif. 8 [%] (dr)
3A (l-Phe) A 99 (99) C
D
46-99 (6)
99 (86)
E (1.5; 0.8) 56/44/0/0 8Acis : 5 (58/42)
[b]
3A’ (dl-Phe) A 99 (0) C 64 (2) F (4; 1.5) 3/2/53/42 8A’cis : 6 (59/41); 8A’trans : 64 (55/45)
[b]
3B (l-Glu) B 79 D 31 F (2; 1.5) 2/1/51/46 8Btrans : 89 (52/48)
[c]
3C (l-Trp) –[d] –[d] D 77 F (2; 1.5) 0/0/63/37 8Ctrans : 85 (59/41)
[c]
3D (l-Met) A 96 D 99 F (2; 1.5) 4/4/53/39 8Dtrans : 64 (56/44)
[c]
3D’ (d-Met) –[d] –[d] D 87 F (2; 1.5) 4/4/53/39 8D’trans : 60 (57/43)
[c]
3E (d-Phg) A 99 D 69 F (3; 2.25) –[b,e] –[b,e]
[a] Chromatographic conditions: see Supporting information. [b] Purified via automated column chromatography (C18). [c] Purified via automated column
chromatography (SiO2). [d] Commercially available. [e] Complex mixture, containing 29% of coupling product of 4E and 7, 4% 8Ecis (dr=62/38) and 11%
8Etrans (dr=51/49).
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35–69% after conventional purification techniques. Additional
separation of the obtained diastereomeric mixtures via prepa-
rative HPLC permitted to isolate the individual diastereomers
10A1, 10A2 and 10A’1, 10A’2 (all trans). The isolated isomers
were used to assess the optical purity of the compounds with
respect to the a-position after the different reaction steps via
chiral HPLC. This technique, however, demonstrated a low
enantiomeric excess (6%) for compounds 10A1 and 10A2,
which implied epimerisation of the a-position of the methyl
ester derived from optically pure l-phenylalanine. Retrospec-
tive analysis of all intermediates revealed that epimerisation
took place already during imination (Scheme 1, Table 1,
Method C), which is not in accordance with preceding literature
reports, stating conservation of the chirality of similar amino
acid-derived imines using comparable or even harsher reaction
conditions (alkaline environment, elevated temperatures).[8] For
this reason, a new imination procedure was tested (Method D),
which did give rise to imine 5A with a considerably higher ee
of 86%.[9] Consequently, this method was applied for the syn-
thesis of the other derivatives 5,8-10B-E as well. As such, our
target library was enlarged by converting the above-men-
tioned a-amino acids 3B–E to b-lactams 10B-E via similar
chemical transformations (Scheme 1, Scheme 2, Table 1,
Table 2). Despite the (presumed) use of chiral imines, a more
or less equimolar amount of the two trans-isomers 8B-E was
obtained in each case, which is in good agreement with the
statement that a chiral imine derived from a chiral amine and
an achiral aldehyde is not an appropriate chiral inductor in the
Staudinger synthesis.[10] Both l- and d-methionine 3D-D’ were
employed individually to be able to use the enriched mixtures
of compounds 10D-D’ for chiral HPLC method optimisation
and determine if the configuration of the chiral centre in a-po-
sition of the carboxylic acid was now conserved throughout
the pathway (Table 2). When compared with l-Phe-derived b-
lactams 10A (synthesised using imination Method C, Table 1,
ee=6%), the epimerisation issue of most other derivatives was
far more limited (e.g. , ee >76% for 10D’, Method D). As ex-
pected, only d-Phg-derived compounds 5,8-10E were com-
pletely racemised as a result of the formation of an extensive
conjugated system after deprotonation at the benzylic posi-
tion.[11] In previous work,[3] it was shown that epimerisation at
the a-position can also take place during subsequent hydroly-
sis, depending on the reagent used. The deprotection reaction
of diastereomerically pure trans ester 10A1 using LiOH·H2O
indeed caused slight epimerisation (Method A, Table 2). SN2-
type dealkylation with LiI resulted in high stereoselectivity but
Table 2. Yields and diastereomeric ratios of intermediate and target products 9–11.
Compound AA Deprotection Acylation Oxidation Hydrolysis
9 [%] (dr) 10A-E [%] (dr) 10F-F’ [%] (dr) Method 11 [%] (dr)
8Atrans
[a] l-Phe 61 (53/47) 35 (53/47)[b,c] – A (on 10A1) ; B (on 10A1) 99 (83/17); 50 (96/4)
8A’cis dl-Phe 90 (59/41) 36 (60/40)
[b] – A 99 (67/33)
8A’trans 90 (58/42) 69 (54/46)
[b,c] – A (on 10A’1-2) ; A (on 10A’2) 99 (69/31); 99 (58/42)
8Btrans l-Glu 70 (53/47) 16 (51/49)
[b] – A[d] 99 (62/38)
8Ctrans l-Trp 89 (51/49) 22 (56/44)
[e] – A 99 (54/46)
8Dtrans l-Met 67 (59/41) 35 (55/45)
[f] – A (on 10D) 99 (66/34)
10F : 30 (62/38)[g,h] A (on 10F) 99 (61/39)
8D’trans d-Met 84 (55/45) 69 (54/46)
[f,h] – A (on 10D’) 99 (58/42)
10F’: 35 (53/47)[f] A (on 10F’) 99 (57/43)
8Ecis d-Phg 38 (66/34) 99 (60/40)
[g,h] – A 99 (74/26)
8Etrans 79 (62/38) 38 (52/48)
[g,h] – A 99 (70/30)
[a] dr=68/32. [b] Purified via automated column chromatography (C18). [c] Additional purification via prep. HPLC permitted to separate the two diastereo-
mers 10Atrans-1 and 10Atrans-2 (6% ee each) and 10A’trans-1 and 10A’trans-2 (0% ee each). [d] 2 equiv. LiOH·H2O were used. [e] Purified via prep. TLC. [f] Purified
via automated column chromatography (SiO2). [g] Purified via prep. TLC. [h] Chiral HPLC analysis was performed on compounds 10D’trans (ee>76%),
10Ecis,trans (ee=0%) and 10Ftrans (ee=85%).
Scheme 2. Functionalisation of key intermediates 8 towards target products 11.
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lower conversion (Method B). Similar results were obtained for
the racemic analogues 10A’. In either way, the loss of enantio-
purity at the a-position was not a major issue as long as the
biological potency of these compounds had not been proven.
Analogues 10B-E were therefore hydrolysed using the LiOH-
mediated procedure.
As mentioned before, in case of methionine-derived ana-
logues 10D-D’, sulphide oxidation was performed prior to hy-
drolysis using meta-chloroperbenzoic acid to bring along the
insertion of two additional hydrogen bond acceptors in a ter-
minal position, which is one of the premised design require-
ments (Figure 1).[3,12] Sulphones 10F-F’ were obtained in this
way without significant loss of enantiopurity at the a-position
(ee(10Ftrans)=85%, Table 2), and could subsequently be hydro-
lysed in quantitative yields relying on LiOH·H2O. As such, this
pathway enabled the preparation of a set of novel cis- and/or
trans-3-acetamido-1-carboxymethyl-4-phenylazetidin-2-ones 11
in a limited amount of six (or seven for 11F-F’) steps in up to
30% overall yield, remarkably more efficient compared with
the synthesis of their C4-unsubstituted analogues (ten steps,
up to 2% overall yield).[3]
The reactant scope of the synthetic pathway can be expand-
ed towards other aromatic or aliphatic aldehydes, combined
with readily available (un)natural a-amino acids, if desired.
In order to provide some preliminary data on the biological
potential of this series of functionalised 3-amino-1-carboxy-
methyl-b-lactams 2 (after neutralisation of 11 with HCl to pro-
vide the corresponding carboxylic acids), the compounds were
subjected to a PBP binding and competition assay. The purified
PBP3 of E. coli K12, PBP5fm of E. faecium D63r and R39 DD-car-
boxypeptidase of Actinomadura spp.[13] were incubated with
acids 2, after which their residual activity (%RA) was deter-
mined by labelling the free enzymes with Bocillin FL, a fluores-
cent reporter molecule and penicillin V analogue (Table 3).[14]
The results revealed the remarkably low residual activity of
PBP3 (10% RA), a lethal target of E. coli, provoked by com-
pound 2Etrans. The inhibitory potency is higher than that of our
initial hit 1A (28% RA),[3] confirming the potential of C4-substi-
tuted, a-aromatic–and therefore nocardicin-like–3-amino-1-car-
boxymethyl b-lactam scaffolds for further PBP inhibitor design.
The unprecedented and highly straightforward six-step syn-
thetic route described in this work, converting simple sub-
strates into highly functionalised C4-(phenyl-)substituted no-
cardicin analogues, might therefore be used to further guide
expansion studies in the future starting from 1-carboxymethyl-
b-lactam 2Etrans as a promising new hit structure (Figure 2).
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